BIO FOr CARE

Autor: Ludolf G. Boven, Yvonne M. Hoedemaekers, J. van der Velden, J. P. van Tintelen, A. A. M. Wilde, S. N. van der Crabben, Dennis Dooijes, Roy Huurman, Folkert W. Asselbergs, Jan D. H. Jongbloed, Judith J.M. Jans, Michelle Michels, Annette F. Baas, R. H. Lekanne Deprez, I. Christiaans, R. A. De Boer, Mandy Jansen
Přispěvatelé: Human genetics, Physiology, ACS - Heart failure & arrhythmias, Graduate School, Surgery, Human Genetics, Amsterdam Reproduction & Development (AR&D), Cardiology, Obstetrics and Gynaecology, Amsterdam Gastroenterology Endocrinology Metabolism, ACS - Pulmonary hypertension & thrombosis, Cardiovascular Centre (CVC)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Netherlands Heart Journal, 29, 6, pp. 318-29
Netherlands Heart Journal, 29(6), 318-329. Bohn Stafleu van Loghum
Jansen, M, Christiaans, I, van der Crabben, S N, Michels, M, Huurman, R, Hoedemaekers, Y M, Dooijes, D, Jongbloed, J D H, Boven, L G, Lekanne Deprez, R H, Wilde, A A M, Jans, J J M, van der Velden, J, de Boer, R A, van Tintelen, J P, Asselbergs, F W & Baas, A F 2021, ' BIO FOr CARE : biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status ', Netherlands Heart Journal, vol. 29, no. 6, pp. 318-329 . https://doi.org/10.1007/s12471-021-01539-w
Netherlands heart journal, 29(6), 318-329. Bohn Stafleu van Loghum
Netherlands Heart Journal, 29, 318-29
Netherlands Heart Journal
Netherlands Heart Hournal, 29, 318-329. Bohn, Stafleu, Van Loghum
ISSN: 1876-6250
1568-5888
DOI: 10.1007/s12471-021-01539-w
Popis: Background Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disease, commonly caused by truncating variants in the MYBPC3 gene. HCM is an important cause of sudden cardiac death; however, overall prognosis is good and penetrance in genotype-positive individuals is incomplete. The underlying mechanisms are poorly understood and risk stratification remains limited. Aim To create a nationwide cohort of carriers of truncating MYBPC3 variants for identification of predictive biomarkers for HCM development and progression. Methods In the multicentre, observational BIO FOr CARe (Identification of BIOmarkers of hypertrophic cardiomyopathy development and progression in Dutch MYBPC3 FOunder variant CARriers) cohort, carriers of the c.2373dupG, c.2827C > T, c.2864_2865delCT and c.3776delA MYBPC3 variants are included and prospectively undergo longitudinal blood collection. Clinical data are collected from first presentation onwards. The primary outcome constitutes a composite endpoint of HCM progression (maximum wall thickness ≥ 20 mm, septal reduction therapy, heart failure occurrence, sustained ventricular arrhythmia and sudden cardiac death). Results So far, 250 subjects (median age 54.9 years (interquartile range 43.3, 66.6), 54.8% male) have been included. HCM was diagnosed in 169 subjects and dilated cardiomyopathy in 4. The primary outcome was met in 115 subjects. Blood samples were collected from 131 subjects. Conclusion BIO FOr CARe is a genetically homogeneous, phenotypically heterogeneous cohort incorporating a clinical data registry and longitudinal blood collection. This provides a unique opportunity to study biomarkers for HCM development and prognosis. The established infrastructure can be extended to study other genetic variants. Other centres are invited to join our consortium.
Databáze: OpenAIRE
Externí odkaz: